Overcoming challenges in implementation of CAR T-cell therapy in resource-constrained settings: Lessons from Brazil and India

This publication has 51 references indexed in Scilit:

• FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
  Clinical Pharmacology & Therapeutics, 2025
• Access to CAR T-cell therapy: Focus on diversity, equity and inclusion
  Blood Reviews, 2023
• Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan
  Cytotherapy, 2022
• CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes
  Cytotherapy, 2022
• Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Special Article: Advanced therapy medicinal products in Brazil: regulatory panorama
  Hematology, Transfusion and Cell Therapy, 2021
• Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care
  Advances in Therapy, 2021
• Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon
  Cytotherapy, 2019
• Treating Adult Acute Lymphoblastic Leukemia in Brazil—Increased Early Mortality Using a German Multicenter Acute Lymphoblastic Leukemia-based regimen
  Clinical Lymphoma Myeloma and Leukemia, 2018
• Declining childhood and adolescent cancer mortality
  Cancer, 2014
• Survival outcome in childhood ALL: Experience from a tertiary care centre in North India
  Pediatric Blood & Cancer, 2009